Stereotaxis Ord Stock Price, News & Analysis

Stereotaxis (NYSE: STXS), a pioneer in surgical robotics, announced the publication of first clinical results for its MAGiC catheter in the Journal of Interventional Cardiac Electrophysiology. The prospective multi-center study demonstrated an impressive 94% acute efficacy rate in treating various heart arrhythmias.

The study, conducted at Copenhagen University Hospital Rigshospitalet and Vilnius University Hospital Santaros Klinikos, included 67 patients with various arrhythmias. The average procedure time was 83 minutes skin-to-skin, with a low procedure-related adverse event rate of 1.5%. Patient enrollment continues with approximately 100 patients enrolled to date, with efficacy assessments ongoing for up to one year.

The MAGiC catheter, designed for robotically-navigated magnetic ablation procedures, showed notable improvements in stability, eliminating the need for sheaths for catheter support. The technology has already been utilized in treating over 150,000 patients across leading hospitals globally.

Stereotaxis (NYSE: STXS) reported Q1 2025 financial results with total revenue of $7.5 million, up 9% year-over-year. Recurring revenue grew 29% to $5.5 million, while system revenue decreased to $2.0 million from $2.6 million. The company reported a net loss of $5.8 million and ended the quarter with $10.7 million in cash and no debt. Key highlights include initial MAGiC commercialization in Europe, successful GenesisX demonstrations, and progress on regulatory efforts. Management reiterated expectations for double-digit revenue growth in 2025, projecting system revenue of $2-3 million per quarter and recurring revenue scaling to $7 million by Q4. The company maintains six active regulatory reviews and anticipates significant adoption of GenesisX pending regulatory approval.

Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, has scheduled its first quarter 2025 financial results release for May 12, 2025 after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. EST to discuss results and corporate developments.

Investors can access the live call by dialing 800-715-9871 (US/Canada) or 1-646-307-1963 (International) with pass code 4794777. A webcast will be available through the investor relations section of Stereotaxis' website, with replay access available for one month after the call.

Stereotaxis' technology has been utilized in treating over 150,000 patients globally across the United States, Europe, Asia, and other regions.

Stereotaxis (NYSE: STXS) announced it will showcase the first-ever live demonstration of its GenesisX Robotic System at the Heart Rhythm Symposium (HRS) in San Diego from April 24-27, 2025. The GenesisX system represents a significant advancement in endovascular surgical robotics, featuring a compact design with built-in magnetic shielding and 80% smaller system cabinet that fits under operating room tables.

The system operates on standard power, requires no structural anchoring, and maintains high performance standards. GenesisX received CE Mark approval in Europe in 2024 and is currently under FDA 510(k) review. The company will also display its portfolio of compatible catheters including Map-iT™, MAGiC™, and EMAGIN™, alongside Synchrony™ and SynX™ digital lab technologies.

Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, has been highlighted at NVIDIA's GTC artificial intelligence conference and accepted into the NVIDIA Connect program. The conference, attended by over 25,000 participants in San Jose, featured Stereotaxis' surgical robots during NVIDIA's VP of Healthcare and Life Sciences' special address.

Stereotaxis' robotic technologies have been utilized in over 150,000 patient treatments across more than 100 leading hospitals globally. The company is now focusing on digital solutions incorporating artificial intelligence, robotic automation, data integration, and decision support capabilities to enhance its robotic systems and operating room environment.

Through the NVIDIA Connect program membership, Stereotaxis gains access to NVIDIA's software development resources, frameworks, and development kits to support its technological advancement initiatives.

Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, announced its participation in the 37th Annual ROTH Conference in Dana Point, California. Chairman and CEO David Fischel will be available for one-on-one meetings on March 17th, 2025.

The company's innovative technology has been utilized to treat over 150,000 patients globally across the United States, Europe, Asia, and other regions. Stereotaxis specializes in developing robotic systems, instruments, and information solutions for the interventional laboratory, focusing on enhancing physician capabilities through robotic precision and safety, while expanding access to minimally invasive therapy and improving operating room productivity and connectivity.

Stereotaxis (NYSE: STXS) has submitted an FDA 510(k) application for its EMAGIN™ 5F catheter, the first robotically navigated catheter designed to expand Robotic Magnetic Navigation into broader endovascular applications. The device is a 5-French diameter catheter guide for navigating complex venous and arterial vasculature.

The EMAGIN brand will include a comprehensive portfolio of robotic catheters and wires, targeting treatments for stroke, cancer, and cardiovascular disease. The company plans to submit for European CE Mark clearance this month and anticipates launching EMAGIN 5F in the second half of 2025 following regulatory approvals.

The catheter is manufactured by Stereotaxis' fully-owned subsidiary Access Point Technologies in Minnesota. The technology aims to enable efficient and safe navigation to difficult-to-reach vascular anatomy, with potential applications in interventional cardiology, radiology, and neurology.

Stereotaxis (NYSE: STXS) has submitted its MAGiC Sweep™ catheter for FDA regulatory clearance, marking a significant milestone as the first high-density EP mapping catheter designed for robotic navigation using Stereotaxis' Robotic Magnetic Navigation systems.

The innovative catheter offers several advantages: rapid electroanatomical mapping from 20 electrodes simultaneously, enhanced safety through atraumatic design, improved access to difficult heart areas, better robotic workflow, and more accurate anatomical mapping. The company plans to submit for European CE Mark clearance this month.

MAGiC Sweep, designed and manufactured by Stereotaxis' subsidiary Access Point Technologies in Minnesota, is expected to launch commercially in the second half of 2025 following anticipated approvals. This development represents the first dedicated diagnostic catheter for Stereotaxis' robotic technology, complementing their existing robotic ablation catheter innovations.

Stereotaxis (NYSE: STXS) reported Q4 2024 financial results with revenue of $6.3 million, up 39% year-over-year. Full-year 2024 revenue reached $26.9 million compared to $26.8 million in 2023.

Q4 breakdown shows system revenue of $1.4 million and recurring revenue of $4.9 million. The company maintains a system backlog of $15.2 million entering 2025. Gross margins were 51% for Q4 and 54% for the full year, with recurring revenue margins at 70% and system revenue at 20%.

The company achieved several milestones including European approval of MAGiC catheter, first GenesisX robot sale, and Chinese regulatory approvals for Genesis and Magbot. Q4 saw positive cash flow of $1.3 million, ending 2024 with $12.4 million cash and no debt.

For 2025, Stereotaxis projects double-digit revenue growth with recurring revenue expected to scale from $5 million in Q1 to $7 million in Q4. System revenue is forecast at $2-3 million per quarter.